Aeon Biopharma, INC

Market Movers (8-K)

See all →
AMEX
AEON Biopharma, Inc. has amended its outstanding two-year milestone warrants, reducing the exercise price and triggering an expected $6.2 million capital raise.
Capital raise
AMEX
AEON Biopharma presented a corporate update on October 23, 2026, detailing progress on its ABP-450 biosimilar candidate, aiming to disrupt the $3.5B neurotoxin market dominated by BOTOX.
Capital raise
AMEX
AEON Biopharma announced receipt of FDA minutes from a Type 2b meeting, which provide clarity on the development pathway for its biosimilar ABP-450, suggesting a potentially more efficient clinical development program.
AMEX
AEON Biopharma reported Q2 2026 results, highlighting a $15.3 million financing with milestone warrants and continued progress in developing its ABP-450 biosimilar to BOTOX.
Capital raise
AMEX
AEON Biopharma, Inc. announced the completion of its public offering, including the partial exercise of an over-allotment option, raising additional capital.
Capital raise
AMEX
Aeon Biopharma announced the pricing of its underwritten public offering, raising up to $13.75 million with potential for additional future funding through milestone warrants.
Capital raise

Quarterly Earnings (10-Q)

See all →
AMEX
AEON Biopharma, Inc. reported continued operating losses and a significant accumulated deficit in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, even after recent capital raises.
Worse than expected
Capital raise
AMEX
AEON Biopharma reported continued operating losses and a strategic pivot to a Botox biosimilar pathway, securing new financing while addressing going concern doubts and NYSE American listing compliance.
Capital raise
Worse than expected
AMEX
AEON Biopharma reported a strategic shift to a biosimilar pathway for ABP-450, raised $18.3M in a public offering, and faces a going concern warning despite improved cash position.
Delay expected
Worse than expected
Capital raise
AMEX
AEON Biopharma, Inc. filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the period ended March 31, 2025, solely to include a previously omitted exhibit related to an amendment to its Amended and Restated Bylaws.
AMEX
AEON Biopharma reports a net income for Q1 2025, driven by fair value adjustments, while navigating strategic changes and substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
AMEX
AEON Biopharma's Q3 2024 results show a net loss, a strategic shift to a biosimilar pathway for ABP-450, and ongoing efforts to secure additional funding.
Worse than expected
Capital raise

Annual Reports (10-K)

See all →
AMEX
AEON Biopharma, Inc. reports significant losses and going concern doubt in its 2025 annual filing, while advancing its ABP-450 botulinum toxin biosimilar program with positive analytical study results and strategic financing efforts.
Worse than expected
Capital raise
AMEX
AEON Biopharma, Inc. has filed an amendment to its 2024 Annual Report on Form 10-K to include inadvertently omitted corporate governance documents, specifically related to its Certificate of Incorporation and Bylaws, without altering any financial or other previously reported information.
AMEX
AEON Biopharma's latest 10-K filing highlights a strategic pivot towards a biosimilar regulatory pathway for ABP-450, while also acknowledging substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional financing.
Worse than expected
Capital raise
AMEX
AEON Biopharma has filed an amendment to its annual report to include exhibits that were inadvertently omitted in the original filing.
AMEX
AEON Biopharma files an amended annual report restating its 2023 financials due to an accounting error related to acquired research and development, and expresses substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
AMEX
AEON Biopharma's annual 10-K filing highlights concerns about its ability to continue as a going concern, despite ongoing clinical trials for its lead product candidate, ABP-450.
Worse than expected
Capital raise

Insider Trading (Form 4)

See all →
AMEX
Alexander Blair Wilson, CLO, CSO and Corp Secretary of AEON Biopharma, Inc., purchased 135,706 shares of common stock on November 20, 2026 for $0.13 per share.
AMEX
Jennifer Sy, Chief Accounting Officer of AEON Biopharma, Inc., purchased 153,846 shares of common stock on November 19, 2026 for $0.13 per share.
AMEX
Robert E. Bancroft, President and CEO and a Director of AEON Biopharma, Inc., purchased 152,333 shares of common stock on November 19, 2026 for $0.13 per share.
AMEX
Daewoong Co., Ltd reported changes in beneficial ownership of AEON Biopharma, Inc. common stock on October 30, 2026.
AMEX
Timothy P Lynch, a 10% owner of AEON Biopharma, Inc., purchased 1,150,000 shares of common stock on August 19, 2026 for $0.21 per share.
AMEX
AEON Biopharma's Chief Financial Officer, John Bencich, acquired 754,717 restricted stock units on April 2, 2026, as part of a long-term incentive plan.

Proxy Statements (Def-14A)

See all →
AMEX
AEON Biopharma, Inc. is holding a Special Meeting of Stockholders on December 15, 2026, to vote on proposals including a reverse stock split, amendments to equity and employee stock purchase plans, and an adjournment proposal.
AMEX
AEON Biopharma, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, detailing proposals for director elections and auditor ratification.
Capital raise
AMEX
AEON Biopharma, Inc. is calling a Special Meeting of Stockholders on January 21, 2026, to approve a private placement, an exchange of convertible notes, and an amended equity incentive plan, all crucial for funding the development of ABP-450 as a biosimilar to BOTOX.
Capital raise
Worse than expected
AMEX
AEON Biopharma announced positive biosimilarity data for ABP-450, strategic financing, and extended cash runway into Q2 2026, alongside its Q3 2025 financial results.
Capital raise
AMEX
AEON Biopharma announced up to $22 million in funding through a private placement and a debt-to-equity exchange with Daewoong, significantly strengthening its balance sheet and accelerating its ABP-450 biosimilar program.
Better than expected
Capital raise
AMEX
AEON Biopharma, Inc. has filed a supplement to its proxy statement to correct an inadvertently stated quorum requirement for its upcoming 2025 Annual Meeting of Stockholders.

New Public Companies (S-1)

See all →
AMEX
AEON Biopharma, Inc. files an S-1MEF to increase its public offering size by $4,528,125, including over-allotment options.
Capital raise
AMEX
AEON Biopharma, Inc. has filed an amendment to its S-1 registration statement, primarily to update the filing fee table related to its proposed stock offering.
Capital raise
AMEX
AEON Biopharma, Inc. has filed a registration statement for a proposed offering of Class A common stock, pre-funded warrants, and milestone warrants.
Capital raise
AMEX
AEON Biopharma shifts strategy to pursue a biosimilar pathway for ABP-450, aiming for FDA approval across multiple therapeutic indications and registering securities for potential resale.
Worse than expected
Capital raise
AMEX
AEON Biopharma is seeking to register the resale of a substantial number of its common stock and warrants, as well as shares issuable upon exercise of existing warrants and options.
Worse than expected
Delay expected
Capital raise
AMEX
AEON Biopharma files for a potential $357 million resale of common stock and warrants, while also eyeing potential capital from warrant exercises.
Worse than expected
Capital raise

Schedule 13D - Activist Investments

AMEX
Daewoong Co., Ltd. and Daewoong Pharmaceutical Co., Ltd. have amended their Schedule 13D filing to report a significant increase in their beneficial ownership of AEON Biopharma, Inc. following a cashless exercise of pre-funded warrants.
AMEX
Daewoong Co., Ltd. and Daewoong Pharmaceutical Co., Ltd. have increased their beneficial ownership in AEON Biopharma, Inc. to 49.99% through an exchange of convertible notes for common stock, a new note, and warrants.
Capital raise
AMEX
Daewoong Co., Ltd. and Daewoong Pharmaceutical Co. Ltd. report their beneficial ownership in AEON Biopharma, Inc. has fallen below 1% due to recent dilution and a reverse stock split.
Worse than expected
Capital raise
AMEX
Robert J. Palmisano and The Palmisano Family, LLC have filed an amended Schedule 13D, revealing a beneficial ownership of 2,265,000 shares, representing approximately 5.7% of AEON Biopharma, Inc.'s Class A Common Stock.
AMEX
Robert J. Palmisano, a director of AEON Biopharma, Inc., and The Palmisano Family, LLC, have disclosed beneficial ownership of 2,265,000 shares, representing a 5.7% stake in the company's Class A Common Stock.

Schedule 13G - Passive Investments

See all →
AMEX
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of 9.9% of AEON Biopharma, Inc. Class A common stock, including shares issuable via warrants.
AMEX
Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 5,048,027 shares, representing 9.99% of AEON Biopharma, Inc.'s Class A common stock.
AMEX
Timothy P. Lynch has filed a Schedule 13G, reporting beneficial ownership of 6,500,000 shares, representing 13.0% of AEON Biopharma's Class A Common Stock.
AMEX
Stonepine Capital Management, LLC and its affiliates have reported a 9.9% beneficial ownership in AEON Biopharma, Inc. Class A Common Stock.
AMEX
Alta Partners LLC has reported a 2.1% beneficial ownership stake in AEON Biopharma, Inc., including shares from warrants, as detailed in its latest Schedule 13G amendment.
AMEX
Alta Partners LLC has disclosed a beneficial ownership of 5.17% of AEON Biopharma, Inc.'s common stock, totaling 586,335 shares.